| abstract |
The present invention relates to a new path to synthesize crystalline Tafamidis polymorphs starting from a Tafamidis acetic acid adduct. In addition, this invention relates to a process to synthesize Tafamidis (2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid * (2R,3R,4R,5S)-6-(methyl-amino)-hexane-1,2,3,4,5-pentol), new Tafamidis crystalline polymorphs, a pharmaceutical compositions comprising the new crystalline polymorphs and to the therapeutic use of such new polymorphs. |